Mark Cuban’s Cost Plus Drugs Partners with Price.com
The two company’s will provide consumers with a platform where they can compare drug prices.
Implications of Novo Nordisk Acquisition of Catalent Reverberate Through Industry
Bruce Phelan of Blue Fin discusses Novo Nordisk's purchase of Catalent manufacturing sites to increase its ability to meet the demand for the popular weight loss drug Wegovy.
Survey: Pharma Execs Are Fully Embracing the Use of AI
The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.
Forecast Predicts Generic Drug Market Will Grow Upwards of $175B Over the Next Three Years
Technavio analysis notes that an increase drug patent expirations could be a contributing factor.
Novo Nordisk’s Parent Company Purchases Catalent for $16.5 Billion
The deal is expected to help boost supply of Wegovy.
2023 Pharmaceutical Executive APEX Award Winners
Navigating Health Insurance Coverage for Innovative and Specialty Drugs: Q&A With Maria Kirsch, President of Patients Services at EVERSANA
Kirsch discusses the complexity of the drugs and the verification process, along with Eversana’s new platform, ACTICS eAccess.